Full-year 2025 guidance: non-GAAP operating margin -- Expected between 23.5% and 24.5%, reflecting increases in sales and ...

BradyScan App Launch -- Announced as available on Android and Apple, supporting barcode generation, scanning, security ...

One clinical-stage biotech is defying gravity—here’s why its record-breaking run is catching institutional attention.

Net Income -- $7.6 million, down from $9.3 million. Net income attributable to Karat ( KRT +1.51%) was $7.3 million, or $0.36 ...

PN-943 (IBD Program) -- Oral, gut-restricted alpha-4-beta-7 integrin antagonist demonstrated greater than threefold improved ...

Disposition Activity -- Q3 proceeds totaled $19.3 million, with $4.6 million in gains; year-to-date sales reached $133.8 ...

gTLD process -- The ICANN 2026 round of new generic Top-Level Domains is intended to start in Q2 2026, with no future ...

Relacorilant NDA updates -- FDA PDUFA date set for Dec. 30, 2025 (hypercortisolism); platinum-resistant ovarian cancer PDUFA ...

Total Revenue -- $21.2 million for the third quarter of 2025, up 16%, driven by MRI compatible IV infusion pump and ...

Recognition -- The company achieved a ranking of 74th in Time Magazine's America's Growth Leaders 2026 list, among over 4,000 ...

Join us as we dissect Lululemon's stock performance and explore whether it can reclaim its former glory in the competitive ...

If you are looking to expand your investments in AI but want to diversify your portfolio away from chip stocks, I think one ...